- Home
- SDHC vs ADPT Comparison
SDHC vs ADPT Comparison
Compare SDHC & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHC
- ADPT
- Stock Information
- Founded
- SDHC 2008
- ADPT 2009
- Country
- SDHC United States
- ADPT United States
- Employees
- SDHC N/A
- ADPT N/A
- Industry
- SDHC
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SDHC
- ADPT Health Care
- Exchange
- SDHC Nasdaq
- ADPT Nasdaq
- Market Cap
- SDHC 1.0B
- ADPT 1.1B
- IPO Year
- SDHC 2024
- ADPT 2019
- Fundamental
- Price
- SDHC $19.03
- ADPT $9.03
- Analyst Decision
- SDHC Hold
- ADPT Buy
- Analyst Count
- SDHC 4
- ADPT 6
- Target Price
- SDHC $30.25
- ADPT $9.83
- AVG Volume (30 Days)
- SDHC 34.2K
- ADPT 3.0M
- Earning Date
- SDHC 05-14-2025
- ADPT 05-01-2025
- Dividend Yield
- SDHC N/A
- ADPT N/A
- EPS Growth
- SDHC N/A
- ADPT N/A
- EPS
- SDHC 1.81
- ADPT N/A
- Revenue
- SDHC $975,463,000.00
- ADPT $189,527,000.00
- Revenue This Year
- SDHC $6.82
- ADPT $21.20
- Revenue Next Year
- SDHC $11.61
- ADPT $21.99
- P/E Ratio
- SDHC $10.54
- ADPT N/A
- Revenue Growth
- SDHC 27.57
- ADPT 8.61
- 52 Week Low
- SDHC $17.03
- ADPT $2.99
- 52 Week High
- SDHC $39.50
- ADPT $10.28
- Technical
- Relative Strength Index (RSI)
- SDHC 46.12
- ADPT 57.82
- Support Level
- SDHC $18.56
- ADPT $8.38
- Resistance Level
- SDHC $19.46
- ADPT $9.51
- Average True Range (ATR)
- SDHC 0.80
- ADPT 0.66
- MACD
- SDHC 0.01
- ADPT 0.16
- Stochastic Oscillator
- SDHC 24.52
- ADPT 63.02
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).